Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785712 | 1.00 | HSP90AA1 (0.32) | HSP90AA1HSP90AB1ALDH1A1CA1CA2 | |
| SCHEMBL1785722 | 1.00 | HSP90AA1 (0.32) | HSP90AA1HSP90AB1ALDH1A1CA1CA2 | |
| SCHEMBL12613573 | 0.84 | MTOR (0.34) | — | |
| SCHEMBL27831856 | 0.77 | — | — | |
| SCHEMBL1080708 | 0.77 | TLR7 (0.31) | HSP90AA1HSP90AB1 | |
| SCHEMBL12613677 | 0.75 | TLK2 (0.30) | — | |
| SCHEMBL12613588 | 0.74 | TLK2 (0.31) | — | |
| SCHEMBL1789979 | 0.74 | TLK2 (0.33) | ALDH1A1MAPT | |
| SCHEMBL1789987 | 0.74 | TLK2 (0.33) | ALDH1A1MAPT | |
| SCHEMBL1789969 | 0.74 | TLK2 (0.33) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | HSP90AA1 1418/4885HSP90AB1 667/4885ALDH1A1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.